💼 Performance Overview
Boston Scientific reported 22.40% YoY revenue growth, fueled by strong demand in Cardiovascular (+28.80%) and MedSurg (+12.40%) segments. The company achieved a 14.80% operating margin, reflecting stable operational performance despite increased expenses.
📊 Key Financial Metrics (YoY Growth)
▫ Revenue: $4.56B vs. $3.73B (+22.40%)
▫ Net Income: $566.00M vs. $504.00M (+12.30%)
▫ Adj. EPS: $0.70 vs. $0.55 (+27.27%)
▫ Gross Margin: 67.85% (-0.73pp)
▫ Operating Margin: 14.80% (-0.30pp)
📍 Segment Breakdown
▫ Cardiovascular: $2.94B (+28.80%)
▫ MedSurg: $1.62B (+12.40%)
📈 Future Outlook
▫ FY 2025 Revenue Guidance: $18.84B - $19.16B (+12.50% to +14.50% YoY)
▫ FY 2025 Adj. EPS Guidance: $2.80 - $2.87
▫ Strategic Focus: Expansion in cardiovascular solutions, digital innovation, and global market penetration.
🔎 Key Takeaway: Boston Scientific delivered one of its best years, driven by product innovation and strong global demand.
